Key result
Antiplatelet drugs, particularly ADP P2Y12 blockers like clopidogrel, prasugrel, and ticagrelor, play a crucial role in reducing adverse ischemic incidents in emergency myocardial infarction treatment.
Population
Patients with myocardial infarction, particularly those undergoing percutaneous coronary intervention.
Design
Review
Authors
Loading...
Supports P2Y12 inhibitor use in acute MI; leaves open optimal agent selection pending new trials.
This review highlights the shift in emergency myocardial infarction treatment towards newer, more potent P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel to better prevent ischemic events.
Komosa et al. (2014) conducted a review in Myocardial infarction. Antiplatelet therapy (clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel) was evaluated. Antiplatelet drugs, particularly ADP P2Y12 blockers like clopidogrel, prasugrel, and ticagrelor, play a crucial role in reducing adverse ischemic incidents in emergency myocardial infarction treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: